Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 adjunctive XEN496 in pediatric KCNQ2 developmental and epileptic encephalopathy
2020-002396-35Phase 3Terminated
- Sponsor
- Xenon Pharmaceuticals
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) and epileptic encephalopathy comparing XEN496 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Percent change from baseline in monthly countable motor seizure frequency. Started Aug 2021; status: terminated.
02
Drugs
XEN496
03
Conditions
KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE)epileptic encephalopathy
Beyond the preview
Go deeper on 2020-002396-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002396-35.